Levi & Korsinsky Reminds Voyager Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - VYGR
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Voyager Therapeutics, Inc. for potential securities law violations. This follows Voyager's announcement about issues with its gene therapy program for ALS, specifically concerning the siRNA payload component of VY9323.
February 18, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Voyager Therapeutics is under investigation for potential securities law violations after announcing issues with its ALS gene therapy program. The siRNA payload of VY9323 showed off-target effects, raising concerns.
The investigation into potential securities law violations and the issues with the ALS gene therapy program are likely to negatively impact investor confidence and the stock price of Voyager Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100